Sort   by:  
 Page size 
UnknownComplete Genome Sequence of the Telford Type S Strain of Mycobacterium avium subsp. paratuberculosis.
Not available
S-EPMC6424202 | biostudies-literature
UnknownAdding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Not available
S-EPMC5455701 | biostudies-literature
UnknownCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.
Not available
S-EPMC3398767 | biostudies-literature
UnknownRadiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Not available
S-EPMC9173627 | biostudies-literature
UnknownAddition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Not available
S-EPMC6692495 | biostudies-literature
UnknownAdding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Not available
S-EPMC5961425 | biostudies-literature
UnknownAddition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Not available
S-EPMC6938598 | biostudies-literature
UnknownAbiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Not available
S-EPMC5533216 | biostudies-literature
UnknownAbiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Not available
S-EPMC8811484 | biostudies-literature
UnknownImplications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
Not available
S-EPMC9804266 | biostudies-literature
Sort   by:  
 Page size